GMP IPO Watch
LIC MF Healthcare Fund
Direct Plan · IDCW · LIC Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.19% | +3.52% | 190 of 255 |
| 1M | +2.19% | +1.97% | 120 of 255 |
| 3M | +1.13% | -3.45% | 22 of 252 |
| 6M | +13.34% | +2.92% | 26 of 251 |
| YTD | +16.66% | +1.21% | 19 of 255 |
| 1Y | +12.92% | +1.11% | 27 of 232 |
| 2Y | +6.83% | +2.39% | 39 of 187 |
| 3Y | +22.53% | +12.36% | 8 of 142 |
| INCEPTION | +20.46% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.52% | +25.30% | -14.55% | 74% | 30% |
| 6M | +10.69% | +33.28% | -10.47% | 74% | 31% |
| 1Y | +18.56% | +64.37% | -5.61% | 88% | 39% |
| 2Y | +15.72% | +29.08% | +3.17% | 100% | 45% |
| 3Y | +22.11% | +24.13% | +19.71% | 100% | 49% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity97.53%
- Debt0.00%
- Cash2.47%
- Other0.00%
Market Cap Split
- Large Cap30.45%
- Mid Cap31.99%
- Small Cap35.09%
- Others2.47%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 46.53 | 41.75 |
| P/B | 6.06 | 6.19 |
| Price / Sales | 6.54 | 5.96 |
| Price / Cash Flow | 33.18 | 30.98 |
| Dividend Yield (%) | 0.43 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 9.59% | -0.50% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 9.07% | -0.22% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 6.14% | -0.24% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 6.04% | -0.41% |
| Apollo Hospitals | Equity | 5.75% | -0.48% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 5.23% | +0.06% |
| Navin Fluorine International | Chemicals & Petrochemicals | 4.98% | -0.67% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 4.97% | +0.18% |
| Aster DM Quality Care | Equity | 4.61% | -0.21% |
| Fortis Healthcare | Equity | 3.77% | -0.01% |
| Metropolis Healthcare | Equity | 3.35% | +0.18% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 3.20% | -0.73% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 3.11% | +0.22% |
| Nephrocare Health Services | Equity | 3.05% | — |
| Max Healthcare Institute | Equity | 2.99% | +0.44% |
View all 27 holdings
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 2.95% | +0.03% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.61% | -0.27% |
| Global Health | Equity | 2.59% | -0.60% |
| Treps | Reverse Repo / TREPS | 2.57% | — |
| Dr. Agarwal's Health Care | Equity | 2.46% | -0.08% |
| Biocon | Pharmaceuticals & Biotechnology | 2.37% | -0.17% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.33% | -0.85% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 2.30% | +0.09% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.43% | — |
| Syngene International | Equity | 1.38% | +0.41% |
| Artemis Medicare Services | Equity | 1.26% | -1.62% |
| Net Receivables / (Payables) | Net Current Assets | -0.10% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.67 | 16.32 | Low Volatility |
| 3Y | 14.21 | 16.10 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.41 | -0.32 | Above Average |
| 3Y | 1.01 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.42 | 0.19 | Above Average |
| 3Y | 2.22 | 1.14 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.02 | 0.96 | Poor Risk Adjusted Returns |
| 3Y | 0.96 | 0.96 | None |
| 5Y | 0.94 | 0.95 | Good Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From LIC Mutual Fund Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| LIC MF Gold Exchange Traded Fund | +16.48% | +31.16% | — | +29.49% |
|
LIC MF Gold ETF Fund of Fund
Direct Plan · Growth
|
+15.94% | +30.72% | — | +29.08% |
|
LIC MF Value Fund
Direct Plan · Growth
|
+15.61% | +16.94% | — | +16.24% |
|
LIC MF Small Cap Fund
Direct Plan · Growth
|
+11.79% | +16.96% | — | +17.10% |
|
LIC MF Manufacturing Fund
Direct Plan · IDCW
|
+10.35% | — | — | +6.74% |
|
LIC MF Arbitrage Fund
Direct Plan · Growth
|
+6.67% | +7.07% | +6.64% | +5.98% |
|
LIC MF Ultra Short Term Fund
Direct Plan · Growth
|
+6.62% | +7.18% | +6.37% | +5.72% |
|
LIC MF Money Market Fund
Direct Plan · Growth
|
+6.50% | +6.74% | — | +6.58% |
|
LIC MF Liquid Fund
Direct Plan · Growth
|
+6.47% | +6.89% | +6.41% | +6.82% |
|
LIC MF Ultra Short to Short Term fund
Direct Plan · Growth
|
+6.11% | +7.27% | +6.57% | +7.16% |
About This Scheme
Investment Objective
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Under normal circumstances, the asset allocation of the Scheme would be as follows: Equity & Equity related instruments of companies engaged in Healthcare and Allied sectors - 80% to 100% of total assets Equity & Equity related instruments of companies engaged in other than Healthcare and Allied sectors, Money market instruments, other liquid instruments, INVITs and mutual fund units including Gold / Silver ETFs - 0% to 20% of total assets. Please refer the Scheme Information Document for complete details.
Exit Load
Nil, If units of the Scheme are redeemed or switched out up to 12% of the units (the limit) within 90 days from the date of allotment. 1% of the applicable NAV, If units of the scheme are redeemed or switched out in excess of the limit within 90 days from the date of allotment. Nil, If units of scheme are redeemed or switched out after 90 days from the date of allotment.
Fund Managers
FM 1: Mr. Sudhanshu Asthana; FM 2: Mr. Dhaval Sangoi
FM1: Primary ; FM2: Comanage
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.